HomeBUSINESS
BUSINESS

Suglat Filed for Type 1 Diabetes in Japan: Astellas/Kotobuki
(Jan.12.2018)

Astellas Pharma has submitted an application in Japan seeking an additional indication of type 1 diabetes for its sodium glucose co-transporter-2 (SGLT-2) inhibitor Suglat (ipragliflozin) ...
(LOG IN FOR FULL STORY)